Story perspectives

Foundayo Shows 0.9 kg Loss, 19% Nausea; FDA Decision Pending

5/13/2026

Summary

Foundayo Weight Loss

ATTAIN-MAINTAIN trial found a 0.9 kg loss in 52 weeks after switching from Wegovy to Foundayo.
Nausea affected 18.8% of Foundayo participants and led to discontinuations in 7.2% versus 6.3% for placebo.
Reducing Zepbound to 5 mg in SURMOUNT-MAINTAIN retained all but 5.6 kg of prior loss, with the continuation arm losing none.
FDA decision on a maintenance indication for Foundayo will shape payer step-therapy and prior-authorization for oral GLP-1 drugs.

Summary

Lilly Clears Trial

Lilly reported that orforglipron showed no new liver safety signals in the ATTAIN-MAINTAIN trial.
The trial met its primary endpoint, leading Lilly to file a regulatory submission for the oral GLP-1 agent.
Executives said the oral pill is less invasive and could expand access to long-term obesity treatment.
Analysts think the pill may cut injectable use and alter prescribing.
Full trial data will be published for independent review.

Summary

Lilly Launches Oral

Lilly introduced Foundayo, the first oral GLP-1 therapy for U.S. patients, in early April 2026.
WHO declared obesity a global public-health crisis, noting more than one billion people live with the condition.
Foundayo’s oral GLP-1 format targets patients who avoid needles, potentially expanding treatment beyond traditional injectable users.
Novo Nordisk launched the Wegovy injectable in 2021 and added an oral pill version earlier this year, signaling a shift toward non-injectable obesity drugs.

Summary

Orforglipron Cuts Costs

Orforglipron costs about $149 per month in the U.S., far less than the over $1,000 monthly price of many injectable weight-loss drugs.
In trials, the oral group kept more than 70 % of initial weight loss while placebo retained only 38-50 %.
Dr Simon Cork notes that blood-pressure, lipid and glucose improvements persisted with the oral therapy despite mild nausea, constipation or diarrhoea that rarely caused discontinuation.

1 of 4

Foundayo Weight Loss

ATTAIN-MAINTAIN trial found a 0.9 kg loss in 52 weeks after switching from Wegovy to Foundayo.
Nausea affected 18.8% of Foundayo participants and led to discontinuations in 7.2% versus 6.3% for placebo.
Reducing Zepbound to 5 mg in SURMOUNT-MAINTAIN retained all but 5.6 kg of prior loss, with the continuation arm losing none.
FDA decision on a maintenance indication for Foundayo will shape payer step-therapy and prior-authorization for oral GLP-1 drugs.

1 / 4